Hypertension Labeling Should Say Classes Are All Effective, But Unequally So
Executive Summary
Antihypertensive drug class labeling for cardiovascular outcomes should specify that some classes of agents are more effective at reducing such events than others, members of FDA's Cardiovascular & Renal Drugs Advisory Committee said
You may also be interested in...
Comparative Research Needs New Approach To Answer Real-Life Questions
To get the most out of the new funding for research on the comparative effectiveness of health care products and services, research needs to go in new directions so that it can answer real-world questions, two former CMS officials said at a recent forum at the American Enterprise Institute
Comparative Research Needs New Approach To Answer Real-Life Questions
To get the most out of the new funding for research on the comparative effectiveness of health care products and services, research needs to go in new directions so that it can answer real-world questions, two former CMS officials said at a recent forum at the American Enterprise Institute
Hypertension Class Labeling Does Not Release Sponsors From Large Trials
FDA should ensure that manufacturers do not construe the addition of outcomes claims to antihypertensive drug labels as lowering the approval standards for future hypertension agents, members of FDA's Cardiovascular & Renal Drugs Advisory Committee emphasized during an April 26 meeting